Fig. 1From: Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritisMCV epitope mapping in responders to RTX. The pattern of recognized MCV epitopes by IgG anti-MCV antibodies (AMCV) of RTX responders (n = 23) were reduced from baseline (a) to 24 weeks (b) after RTX treatment (x axis: wells A to H; y axis: wells 1 to 12; z axis: number of positive patients)Back to article page